Selpercatinib received its accelerated approval by the FDA in May 2020 for metastatic RET-fusion+ NSCLC and papillary thyroid cancers and RET-mutant medullary thyroid cancer, based on the LIBRETTO-001 trial evaluating its activity in RET + advanced solid tumors14–16. The gene discussed is RET; the disease is thyroid gland papillary carcinoma.